Literature DB >> 841350

Metastatic and histologic presentations in unknown primary cancer.

J S Nystrom, J M Weiner, J Heffelfinger-Juttner, L E Irwin, J R Bateman, R M Wolf.   

Abstract

The patient with metastatic adeno- or undifferentiated carcinoma who presents with a cryptic primary is subjected to an extensive diagnostic search. These efforts apparently stem from the following assumptions: 1). The ultimately proven primary sites in such patients will occur with the same frequency as the most commonly occurring carcinomas (i.e., lung, breast, colon, prostate, etc.); and 2). Metastatic patterns and histologies seen at diagnosis are the same as for patients presenting with these more common tumors. Our data contradict these assumptions. For example, the most commonly occurring unknown primary was pancreas. Rarely occurring primaries included breast and prostate. Lung cancer was observed frequently, but the presentation was atypical because of the large proportion of female patients. In addition, the metastatic patterns at diagnosis were unusual for many of the ultimately proven primary sites. In an attempt to deal with these contradictions, a method to search for new relationships between primary site and metastatic-histologic presentations was employed. This method succeeded in placing the location of the primary cancer to above or below the diaphragm in 80% of the patients studied retrospectively. Tested prospectively in a small group of patients, the method appears to be clincally useful. Finally, in this study we have made the diagnosis, antemortem, of the primary cancer site (PCS) in only 30 of 264 patients. The failure to find the primary site, dispite extensive radiologic work-up, was disappointing to the authors, and emphasizes the difficulty of finding PCS antemortem. In our study pancreas and lung appear to be most common cryptic primary sites.

Entities:  

Mesh:

Year:  1977        PMID: 841350

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  30 in total

1.  Cancer of unknown primary site.

Authors:  J E Ultmann
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Secondary malignancies of the uterine cervix: a potential diagnostic pitfall.

Authors:  Gian Franco Zannoni; Valerio Gaetano Vellone; Marco Petrillo; Guido Fadda; Esther Diana Rossi; Giovanni Scambia; Arnaldo Carbone
Journal:  Virchows Arch       Date:  2013-06-10       Impact factor: 4.064

3.  Tumour marker immunoreactivity in adenocarcinoma.

Authors:  I O Ellis; A Hitchcock
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

4.  Chasing the unknown primary.

Authors: 
Journal:  Br Med J       Date:  1980-11-08

5.  A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.

Authors:  Jinhai Yan; Qingzhu Wei; Wenjing Jian; Jianghuan Liu; Hongping Tang; Juan Ge; Jie Zhou; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 6.  Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Authors:  John D Hainsworth; F Anthony Greco
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

7.  Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East.

Authors:  Nobuaki Matsubara; Hirofumi Mukai; Shunji Nagai; Kuniaki Itoh
Journal:  Int J Clin Oncol       Date:  2010-08-11       Impact factor: 3.402

Review 8.  [Prognosis-adapted surgical management of bone metastases].

Authors:  S Utzschneider; P Weber; A Fottner; B Wegener; V Jansson; H R Dürr
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

9.  Diagnosis of ovarian cancers using thoracoscopy: Three case reports and review of the literature.

Authors:  Makoto Nakao; Tetsuya Oguri; Mikinori Miyazaki; Takehiro Uemura; Osamu Takakuwa; Eiji Kunii; Hirotsugu Ohkubo; Ken Maeno; Shigeki Sato
Journal:  Exp Ther Med       Date:  2012-04-11       Impact factor: 2.447

10.  [Whole-body MRI in comparison to skeletal scintigraphy for detection of skeletal metastases in patients with solid tumors].

Authors:  N Ghanem; T Kelly; C Altehoefer; J Winterer; O Schäfer; T A Bley; E Moser; M Langer
Journal:  Radiologe       Date:  2004-09       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.